Vinblastine, adriamycin, thiotepa, and halotestin (VATH). Therapy for advanced breast cancer refractory to prior chemotherapy

Marjorie Perloff, Ronald D. Hart, James F. Holland

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

Nineteen postmenopausal patients with metastatic breast cancer refractory to conventional combination chemotherapy were treated with monthly cycles with the combination of vinblastine, adriamycin, thiotepa and halotestin. Ten patients (52%) responded with a greater than 50% regression of measurable tumor. The median duration of response was 11.5 months, with 5/10 patients still responding at a mean follow‐up of 10 months. Only 2/10 responders have died with a mean follow‐up of 13.8 months. In contrast, 8/9 nonresponders have died (median survival 6.0 months). Response to therapy was neither in fluenced by site of disease, time interval from diagnosis to primary chemotherapy nor duration of response to primary chemotherapy. No patient was hospitalized because of drug induced toxicity. This combination of drugs is a tolerable effective regimen for patients relapsing after adjuvant chemotherapy or after primary combination chemotherapy for grossly metastatic disease. Cancer 42:2534–2537, 1978.

Original languageEnglish
Pages (from-to)2534-2537
Number of pages4
JournalCancer
Volume42
Issue number6
DOIs
StatePublished - Dec 1978

Fingerprint

Dive into the research topics of 'Vinblastine, adriamycin, thiotepa, and halotestin (VATH). Therapy for advanced breast cancer refractory to prior chemotherapy'. Together they form a unique fingerprint.

Cite this